KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Common Equity (2016 - 2025)

Historic Common Equity for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $1.0 billion.

  • Supernus Pharmaceuticals' Common Equity rose 422.15% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 422.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 1239.45% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Common Equity of $1.0 billion as of Q3 2025, which was up 422.15% from $1.1 billion recorded in Q2 2025.
  • Supernus Pharmaceuticals' Common Equity's 5-year high stood at $1.1 billion during Q2 2025, with a 5-year trough of $754.4 million in Q1 2021.
  • In the last 5 years, Supernus Pharmaceuticals' Common Equity had a median value of $912.2 million in 2023 and averaged $911.3 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Common Equity surged by 2299.72% in 2021 and then soared by 186.55% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Common Equity stood at $815.9 million in 2021, then rose by 8.62% to $886.2 million in 2022, then grew by 3.98% to $921.5 million in 2023, then increased by 12.39% to $1.0 billion in 2024, then increased by 1.35% to $1.0 billion in 2025.
  • Its Common Equity was $1.0 billion in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.0 billion in Q1 2025.